Research programme: transforming growth factor-beta1 inhibitor - Digna Biotech

Drug Profile

Research programme: transforming growth factor-beta1 inhibitor - Digna Biotech

Alternative Names: NAFB002; NAFB002 P17; P 17

Latest Information Update: 09 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Digna Biotech
  • Class Peptides
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Bone metastases; Corneal ulcer; Dry eyes; Fibrosis; Malignant melanoma

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Spain (Ophthalmic)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone metastases in Spain (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top